Discrepancies between various methods in susceptibility testing and epidemiological analysis of stenotrophomonas mal tophilia clinical isolates

Central European Journal of Public Health

Volumn 18, Issue 2, 2010, Pages 119-123

  Masgala, Aikaterini ^a   Galani, Irene ^a   Souli, Maria ^a   Giamarellou, Helen ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Broth microdilution; Disk diffusion; E test; Epidemiological analysis

Indexed keywords

EID: 77957572252     PISSN: 12107778     EISSN: None     Source Type: Journal    
DOI: 10.21101/cejph.a3571     Document Type: Article

References (28)

1. VanCouwenberghe CJ, Farver TB, Cohen SH. Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens. Infect Control Hosp Epidemiol. 1997 May;18(5):316-21.
2. Friedman ND, Korman TM, Fairley CK, Franklin JC, Spelman DW. Bacteraemia due to Stenotrophomonas maltophilia; an analysis of 45 episodes. J Infect. 2002 Jul;45(1):47-53.
3. Arpi M, Victor MA, Mortensen I, Gottschau A, Bruun B. In vitro susceptibility of 124 Xanthomonas maltophilia (Stenotrophomonas maltophilia) isolates: comparison of the agar dilution method with the E-test and two agar diffusion methods. APMIS. 1996 Jan;104(2):108-14.
4. Hohl P, Frei R, Aubry P. In vitro susceptibility of 33 clinical case isolates of Xanthomonas maltophilia. Inconsistent correlation of agar dilution and of disk diffusion test results. Diagn Microbiol Infect Dis. 1991 Sep-Oct;14(5):447-50.
5. Traub WH, Leonhard B, Bauer D. Antibiotic susceptibility of Stenotrophomonas (Xanthomonas) maltophilia: comparative (NCCLS criteria) evaluation of antimicrobial drugs with the agar dilution and the agar disk diffusion (Bauer-Kirby) tests. Chemotherapy. 1998 May-Jun;44(3):164-73.
6. Yao JD, Louie M, Louie L, Goodfellow J, Simor AE. Comparison of E-test and agar dilution for antimicrobial susceptibility testing of Stenotrophomonas (Xanthomonas maltophilia. J Clin Microbiol. 1995 May;33(5):1428-30.
7. Dembry LM, Farrel PA, Orcutt DR, Gerrity LA, Andriole VT. In vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest. J Antimicrob Chemother. 1997 Jun;39 Suppl B:35-42.
8. MacKenzie FM, Smith SV, Milne KE, Griffiths K, Legge J, Gould IM. Antibiograms of resistant Gram-negative bacteria from Scottish CF patients. J Cyst Fibros. 2004 Aug;3(3):151-7.
9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Eighteenth Informational Supplement M100-S18. Wayne: CLSI; 2008.
10. Berg G, Roskot N, Smalla K. Genotypic and phenotypic relationships between clinical and environmental isolates of Stenotrophomonas mal-tophilia. J Clin Microbiol. 1999 Nov;37(11):3594-600.
11. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995 Sep;33(9):2233-9.
12. Jones RN, Sader HS, Beach ML. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). Int J Antimicrob Agents 2003 Dec;22(6):551-6
13. Liaw SJ, Teng LJ, Hsueh PR, Ho SW, Luh KT. In vitro activities of antimicrobial combinations against clinical isolates of Stenotrophomonas maltophilia. J Formos Med Assoc. 2002 Jul;101(7):495-501.
14. Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, et al; Gemifloxacin Surveillance Study Research Group. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study. Eur J Clin Microbiol Infect Dis. 2001 Nov;20(11):814-9.
15. Di Bonaventura G, D'Antonio D, Catamo G, D'Ercole S, Piccolomini R. Comparative in vitro activity of levofloxacin and ciprofloxacin against bacterial isolates from neutropenic patients. Chemotherapy. 2002 Jul;48(3):134-7.
16. Ribera A, Jurado A, Ruiz J, Marco F, Del Valle O, Mensa J, et al. In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine. Diagn Microbiol Infect Dis. 2002 Feb;42(2):123-8.
17. Hanberger H, Nilsson LE; Swedish Study Group. High frequency of antibiotic resistance among Gram-negative isolates in ICUs at 10 Swedish hospitals. Clin Microbiol Infect. 1997 Apr;3(2):208-15.
18. Hejnar P, Hamal P, Koukalová D. Influence of an extended incubation period on values of MIC of antibiotics in Stenotrophomonas maltophilia clinical strains. New Microbiol. 2000 Oct;23(4):415-21.
19. Tatman-Otkun M, Gürcan S, Ozer B, Aydoslu B, Bukavaz S. The antimicrobial susceptibility of Stenotrophomonas maltophilia isolates using three different methods and their genetic relatedness. BMC Microbiol. 2005 May 9;5:24.
20. Gülmez D, Hasçelik G. Stenotrophomonas maltophilia: antimicrobial resistance and molecular typing of an emerging pathogen in a Turkish university hospital. Clin Microbiol Infect. 2005 Nov;11(11):880-6.
21. Pankuch GA, Jacobs MR, Rittenhouse SF, Appelbaum PC. Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and cip-rofloxacin tested by five methods. Antimicrob Agents Chemother. 1994 Oct;38(10):2317-22.
22. Carroll KC, Cohen S, Nelson R, Campbell DM, Claridge JD, Garrison MW, et al. Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis. 1998 Nov;32(3):229-35.
23. Krueger TS, Clark EA, Nix DE. In vitro susceptibility of Stenotro-phomonas maltophilia to various antimicrobial combinations. Diagn Microbiol Infect Dis. 2001 Sep-Oct;41(1-2):71-8.
24. San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2004 Jan;48(1):168-71.
25. Valdezate S, Vindel A, Martín-Dávila P, Del Saz BS, Baquero F, Cantón R. High genetic diversity among Stenotrophomonas maltophilia strains despite their originating at a single hospital. J Clin Microbiol. 2004 Feb;42(2):693-9.
26. Karelová E, Křížová P, Musílek M. MLEE and PFGE characterization of Neisseria meningitis serogroup C and B isolated in the Slovak Republic in 1998. Cent Eur J Public Health. 2002 Jun;10(1-2):60-5.
27. Poulos CD, Matsumura SO, Willey BM, Low DE, McGeer A. In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob Agents Chemother. 1995 Oct;39(10):2220-3.
28. Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother. 1994 Mar;38(3):624-7.